Paper Details

  1. Home
  2. Paper Details

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

Author: BleeckerEugene R, BusseWilliam W, CastroMario, GossageDavid L, KhatryDeepak B, KolbeckRoland, KunaPiotr, MolfinoNestor A, PizzichiniEmilio, RaibleDonald G, WangBing, WardChristine K, WenzelSally E, WuYanping, van der MerweRené

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, depletes blood and airway eosinophils and is being studied as a treatment for uncontrolled eosinophilic asthma.
Paper Details　
Original Abstract of the Article :
Persistent eosinophilic airway inflammation in asthma increases the risk of exacerbations. In a phase 2b dose-ranging study, we aimed to assess the efficacy and safety of benralizumab, an anti-interleukin 5 receptor α monoclonal antibody that depletes blood and airway eosinophils, in adults with unc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2213-2600(14)70201-2

データ提供：米国国立医学図書館（NLM）

Benralizumab, an Anti-interleukin 5 Receptor α Monoclonal Antibody, versus Placebo for Uncontrolled Eosinophilic Asthma: A Phase 2b Randomised Dose-ranging Study

This study investigates the efficacy and safety of benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, in treating uncontrolled eosinophilic asthma. The researchers focused on benralizumab's ability to deplete blood and airway eosinophils, a type of white blood cell that contributes to inflammation in asthma.

The phase 2b dose-ranging study found that benralizumab effectively reduced blood and airway eosinophils, leading to improvements in asthma control and a reduction in exacerbations. The study demonstrated that benralizumab was well-tolerated, with a favorable safety profile. The researchers concluded that benralizumab shows promise as a new treatment option for uncontrolled eosinophilic asthma, particularly in patients who do not respond well to standard therapies.

Benralizumab: A New Weapon Against Uncontrolled Eosinophilic Asthma

This study provides compelling evidence for the effectiveness of benralizumab in treating uncontrolled eosinophilic asthma. The study's findings suggest that benralizumab could be a valuable addition to the therapeutic arsenal for managing this challenging condition. The researchers' findings are a testament to the ongoing advancements in asthma treatment and the development of targeted therapies that address specific underlying mechanisms of disease.

Understanding Eosinophilic Asthma

Eosinophilic asthma is a type of asthma characterized by an elevated number of eosinophils in the airways. This study investigates the efficacy of benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, in treating this form of asthma. The study's findings could lead to improved treatment strategies and better management of eosinophilic asthma.

Dr.Camel's Conclusion

This study demonstrates the potential of targeted therapies for treating specific types of asthma. Benralizumab's efficacy in reducing eosinophils and improving asthma control is a significant development. This research provides hope for individuals with uncontrolled eosinophilic asthma, offering a new treatment option that may provide relief and improve their quality of life.

Date :
  1. Date Completed 2015-11-17
  2. Date Revised 2017-11-16
Further Info :

Pubmed ID

25306557

DOI: Digital Object Identifier

10.1016/S2213-2600(14)70201-2

Related Literature

Article Analysis
・Effects of benralizumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.